Equinox Gold Corp. Common Shares vs Smith & Nephew plc — how do they compare? Equinox Gold Corp. Common Shares trades at $11.4 (market cap $12.80B), while Smith & Nephew plc trades at $27.21 (market cap $11.31B). The key difference: Equinox Gold Corp. Common Shares and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Equinox Gold Corp. Common Shares for 0 Days and Smith & Nephew plc for 120 Days on average.
| EQX | SNN | |
|---|---|---|
Market Cap | $12.80B | $11.31B |
Volume | 8,210,537 | 1,050,005 |
Sector | Basic Materials | Health |
52-Week High | $18.76 | $37.17 |
52-Week Low | $8.62 | $26.42 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $12.90B | $14.35B |
Dividend Yield | 0.48% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Equinox Gold is a gold mining company with operations in the Americas. It produces gold and develops additional mining projects.
Read more on EQX →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →